Andipal tablets, No. 10
Instructions
Andipalum-V Instructions for Use
Composition
Active ingredients: metamizole sodium (analgin); bendazol hydrochloride; papaverine hydrochloride;
1 tablet contains:
- 250 mg (0.25 g) of metamizole sodium (analgin),
- bendazol hydrochloride 20 mg (0.02 g),
- papaverine hydrochloride 20 mg (0.02 g);
excipients: potato starch, calcium stearate, talc.
Dosage Form
Tablets.
Main physical and chemical properties:
Tablets are white or white with a slight yellowish tint, with a flat surface, beveled edges, and a score line.
Pharmacotherapeutic group
Analgesics and antipyretics.
ATC code N02B B52.
Pharmacological properties
Pharmacodynamics.
A combination drug with analgesic, antispasmodic, and vasodilatory effects resulting from the specific actions of its components. The drug also has antihypertensive and antipyretic effects.
Metamizole sodium—a nonsteroidal anti-inflammatory drug (NSAID) belonging to the pyrazolone derivative group—exhibits anti-inflammatory, analgesic, and antipyretic effects, the mechanism of action of which is due to the inhibition of COX and the blocking of prostaglandin synthesis from arachidonic acid, as well as the disruption of the transmission of pain-relatedand proprioceptive impulses, an increase in the excitability threshold of the thalamic pain sensitivity centers, and increased heat dissipation.
Bendazol hydrochloride has vasodilatory, antispasmodic, hypotensive effects; it also stimulates spinal cord function, promotes the restoration of peripheral nerve function, and exerts a moderate immunostimulatory effect.
Papaverine hydrochloride has myotropic, antispasmodic, and hypotensive effects. It blocks phosphodiesterase, promotes the accumulation of cAMP and reduces intracellular calcium levels, and relaxes the smooth muscles of blood vessels and internal organs.
Pharmacokinetics.
When taken orally, it is rapidly and completely absorbed. It is hydrolyzed in the intestinal walls to form an active metabolite. The effect begins within 20–40 minutes and reaches its peak after 2 hours. It is metabolized in the liver. It is excreted by the kidneys.
Indications
Pain associated with vasospasm or spasm of the smooth muscles of internal organs.
Contraindications for Andipal-B
- Known or suspected hypersensitivity to any of the ingredients in the medication, or to pyrazolone derivatives (butadione, tribuzone, antipyrine);
- suspected acute surgical pathology;
- conditions characterized by decreased muscle tone or convulsive syndrome;
- glaucoma, traumatic brain injury, severe heart failure, AV block, arterial hypotension, diabetes mellitus, hypothyroidism, adrenal insufficiency, prostatic hypertrophy, congenital glucose-6-phosphate dehydrogenase deficiency, anemia of any etiology, cytostatic or infectious neutropenia, leukopenia, agranulocytosis, thrombocytopenia, hepatoporphyria, severe liver and kidney dysfunction, porphyria, chronic nephritis with edema and impaired renal nitrogen excretion, bronchial asthma, comatose state, respiratory depression, bronchial obstructive syndrome, gastric and duodenal ulcers accompanied by bleeding;
- hypotonic colitis, chronic constipation;
- concomitant use of monoamine oxidase (MAO) inhibitors.
- Age over 75 years (risk of hyperthermia).
Interactions with other medications and other types of interactions.
Radiopaque agents, colloidal blood substitutes, penicillin: should not be used during treatment with metamizole sodium.
Nonsteroidal anti-inflammatory drugs (NSAIDs): their analgesic and antipyretic effects are potentiated, and the likelihood of additive adverse effects increases.
Oral hypoglycemic agents, indirect anticoagulants, glucocorticosteroids, phenytoin, indomethacin: metamizole sodium increases the activity of these drugs by displacing them from their protein-binding sites.
Methotrexate: high doses of metamizole sodium may lead to increased plasma concentrations of methotrexate and an intensification of its toxic effects (primarily on the gastrointestinal tract and the hematopoietic system).
Diuretics (furosemide): the diuretic effect may be reduced.
Sulfonylurea hypoglycemic agents: enhanced hypoglycemic effect.
Ethanol: metamizole sodium enhances its sedative effect.
Levodopa, methyldopa: reduced hypotensive effect of methyldopa and reduced antiparkinsonian effect of levodopa.
Cyclosporine: Concomitant use reduces the concentration of cyclosporine in the blood.
Nitrofurantoin: there are reports of hepatitis developing with concomitant use of this drug.
Sarcolysin, thiamazole (methimazole), and drugs that suppress bone marrow activity, including gold-based preparations: the risk of hematotoxicity, including the development of leukopenia, is increased.
Phenylbutazone, glutethimide, barbiturates, and other inducers of hepatic microsomal enzymes reduce the efficacy of metamizole sodium.
Sedatives, tranquilizers (diazepam, trimethazine, etc.), codeine, anaprilin, H2-histamine receptor blockers, and propranolol enhance the analgesic effect of metamizole sodium.
Tricyclic antidepressants (amitriptyline, doxepin, etc.), hormonal contraceptives, and allopurinol: concomitant use of metamizole sodium with these drugs may increase its toxicity.
Antihypertensive drugs (agents affecting the renin-angiotensin system), antidepressants, antispasmodics, sedatives, diuretics, saluretics, procainamide, reserpine, quinidine, phentolamine: increased hypotensive effect.
Chlorpromazine or other phenothiazine derivatives: severe hypothermia may develop.
Phentolamine: potentiates the effect of papaverine on the corpus cavernosum of the penis.
Cardiac glycosides: marked enhancement of myocardial contractility due to a decrease in total peripheral vascular resistance.
Morphine: may reduce the antispasmodic activity of papaverine.
Adsorbents, astringents, and coating agents: reduced absorption of the drug from the gastrointestinal tract.
The drug’s effectiveness is reduced in smokers.
Caution is advised when using this drug concomitantly with salicylates.
Special Considerations for Use
Do not exceed the recommended doses of the drug. Since metamizole sodium has anti-inflammatory and analgesic properties, it may mask signs of infection, symptoms of non-infectious diseases, and complications associated with pain, which may complicate their diagnosis. Do not use this medication to relieve acute abdominal pain until the cause has been determined.
While taking this medication, avoid alcohol and drugs that depress the central nervous system.
This medication should be used with caution in patients:
- with existing allergic conditions (including hay fever) or a history of such conditions, due to an increased risk of allergic reactions;
- with inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease;
- with cardiovascular insufficiency;
- who are prone to hypotension;
- with supraventricular tachycardia;
- with a history of kidney disease (pyelonephritis, glomerulonephritis);
- with impaired liver and/or kidney function.
Use this medication with caution in patients with a history of chronic alcohol abuse, in debilitated patients, and in the elderly due to the risk of hyperthermia and an increased incidence of adverse reactions, particularly gastrointestinal ones; when used concomitantly with cytostatic drugs (only under medical supervision). Use this medication with caution in cases of reduced intestinal motility.
Discontinue the medication immediately and seek medical attention without delay if unexplained chills, fever, sore throat, difficulty swallowing, bleeding gums, or pallor of the skin occur, skin or mucous membrane rashes, asthenia, or the development of vaginitis or proctitis. If symptoms of liver dysfunction occur, including gastrointestinal disturbances, jaundice, and elevated liver enzyme levels, discontinue use of the medication. Inform your doctor if you experience the following symptoms: hot flashes, sweating, headache, increased fatigue, jaundice, nausea, abdominal discomfort, or constipation.
While taking this medication, urine may turn red due to the excretion of a metabolite of metamizole sodium; this has no clinical significance. Orthostatic hypotension may occur while taking this medication.
While taking this medication, peripheral blood counts (white blood cell differential) should be monitored.
Do not use the drug for longer than the prescribed duration without consulting a doctor. Regular, long-term use of the drug is not recommended due to the myelotoxicity of metamizole sodium. During prolonged use of the drug (more than 7 days), peripheral blood counts (due to the myelotoxicity of metamizole), as well as kidney and liver function, must be monitored.
When administered to children, constant medical supervision is required.
Smoking reduces the drug’s effectiveness.
If symptoms do not begin to subside, or if, conversely, the patient’s condition worsens or adverse effects occur, discontinue use of the drug and consult a physician regarding further treatment.
Use during pregnancy or breastfeeding.
Use during pregnancy or breastfeeding is not recommended.
Effect on reaction time when driving or operating machinery.
While taking this medication, you should avoid driving or operating complex machinery.
Dosage and Administration of Andipal-B
Adults and children 12 years of age and older should take 1–2 tablets 2–3 times daily by mouth. The maximum daily dose is 6 tablets.
The duration of treatment depends on the nature and course of the disease, the therapeutic effect achieved, and the nature of the comprehensive pharmacotherapy being administered; however, treatment should not exceed 3 days.
Children.
Not recommended for use in children under 12 years of age.
Overdose
Symptoms: hypothermia, marked decrease in blood pressure, arrhythmia, tachycardia, partial or complete atrioventricular block, acute agranulocytosis, neutropenia, hemorrhagic syndrome, respiratory muscle paralysis, hyperventilation, decreased tissue perfusion, headache, restlessness, lethargy, drowsiness, dizziness, delirium, impaired consciousness, visual disturbances, ataxia, nystagmus, diplopia, tinnitus, central nervous system depression, convulsive syndrome, collapse, coma, cyanosis, metabolic acidosis, hyperglycemia, hyperkalemia, oliguria, anuria, dysphagia, nausea, vomiting, diarrhea, constipation, gastrointestinal disorders, gastralgia, gastritis, liver dysfunction, acute renal and/or hepatic failure, skin rash, shortness of breath, moderate dyspnea, skin flushing, general weakness, palpitations, sensation of heat, increased sweating.
Treatment: discontinuation of the drug, induction of vomiting, gastric lavage, maintenance of blood pressure, administration of enterosorbents and saline laxatives, forced diuresis, symptomatic therapy aimed at maintaining vital functions. In severe cases, hemodialysis, hemoperfusion, or peritoneal dialysis may be required.
At the first signs of overdose, seek medical attention immediately.
Side Effects of Andipal-B
Immune system:
Hypersensitivity reactions may occur, including:
- rash on the skin and mucous membranes,
- itching,
- facial flushing,
- skin flushing,
- hives,
- conjunctivitis,
- a burning sensation in the throat,
- dry cough,
- runny nose,
- difficulty breathing,
- angioedema,
- bronchospastic syndrome,
- anaphylactic shock,
- Stevens-Johnson syndrome,
- Lyell’s syndrome.
Central nervous system:
- drowsiness,
- excessive sweating,
- dizziness,
- headache,
- anorexia.
Cardiovascular system:
- AV block,
- arrhythmias,
- ventricular extrasystoles,
- decreased cardiac output,
- decreased blood pressure,
- chest pain,
- hot flashes,
- palpitations,
- feeling of heat,
- hyperthermia,
- weakness,
- numbness,
- tremors,
- loss of consciousness;
- with prolonged use—deterioration of ECG parameters, ventricular fibrillation, asystole, ventricular flutter, orthostatic hypotension, collapse, apnea.
Blood and lymphatic system disorders:
- with prolonged use, leukopenia,
- granulocytopenia,
- agranulocytosis,
- anemia,
- thrombocytopenia;
- eosinophilia.
Gastrointestinal:
- dry mouth,
- nausea,
- abdominal discomfort,
- constipation,
- elevated liver transaminases,
- jaundice,
- hepatitis.
Hepatobiliary system:
- hepatitis.
Urinary system:
- usually in patients with impaired renal function and/or when excessive doses are used—transient oliguria, anuria, proteinuria, interstitial nephritis, red-colored urine.
If any adverse reactions occur, discontinue use of the drug and be sure to consult a doctor.
Shelf life
2 years.
Storage Conditions
Store in the original packaging at a temperature not exceeding 25°C.
Keep out of reach of children.
Packaging
10 tablets per strip;
10 tablets per strip; 1 strip per paper envelope;
10 tablets per strip; 2 or 10 strips per cardboard package;
10 tablets per blister; 1, 2, or 10 blisters per cardboard box.
Pharmacy dispensing category
Over-the-counter – No. 10.
By prescription – No. 20, No. 100.
Similar products
Products from the same category









